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Abstract
Background In order to improve injury assessment of brain
injuries, protein markers of pathophysiological processes and
tissue fate have been introduced in the clinic. Themost studied
protein Bbiomarker^ of cerebral damage in traumatic brain
injury (TBI) is the protein S100B. The aim of this narrative
review is to thoroughly analyze the properties and capabilities
of this biomarker with focus on clinical utility in the assess-
ment of patients suffering from TBI.
Results S100B has successfully been implemented in the clin-
ic regionally (1) to screen mild TBI patients evaluating the
need to perform a head computerized tomography, (2) to pre-
dict outcome in moderate-to-severe TBI patients, (3) to detect
secondary injury development in brain-injured patients and
(4) to evaluate treatment efficacy. The potential opportunities
and pitfalls of S100B in the different areas usually refer to its
specificity and sensitivity to detect and assess intracranial
injury.
Conclusion Given some shortcomings that should be realized,
S100B can be used as a versatile screening, monitoring and
prediction tool in the management of TBI patients.
Keywords S100B . Traumatic brain injury . Outcome .
Monitoring . Screening . Biomarker . Serum . Humans
Introduction
Traumatic brain injury (TBI) is a common cause of death and
disability, primarily in the young but increasingly among the
elderly [153]. The injury panorama stretches from the severely
injured, unconscious patients in need of neuro-intensive care
to the more common mildly injured patients, sometimes with-
out any visual lesions. Many survivors, even from seemingly
mild injuries, may suffer from permanent disabilities and be in
need of long-term rehabilitation with high costs for society
[56].
TBI is a complex disease and may change symptomatology
over time [102]; it is heterogenic in nature and may contain a
plethora of different hemorrhagic and non-hemorrhagic in-
jures, both inside and outside the brain parenchyma. At ad-
mission to the hospital, the physicians often rely solely on a
neurological examination and a computerized tomography
(CT) scan, as other more advanced radiological options are
unavailable in the acute care setting and monitoring tools are
available only in specialized neuro-intensive care units
(NICUs). Consequently, the assessment methods are often
limited, and better surrogate markers of brain injury have been
sought to help the treating clinician. In many fields of medi-
cine, biological markers (Bbiomarkers^) of injury have been
introduced. A biomarker is defined as BA characteristic that is
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objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention^ [54]. It may be pro-
teins, functioning as surrogate indicators of injury, such as
troponin-T in the screening for myocardial infarction [60]
and D-dimer for deep vein thrombosis [198]. While a number
of potential markers of brain tissue fate (i.e., increasing levels
of the specific markers indicating affected or dying cells) ex-
ist, the most studied protein biomarker of brain injury is
S100B.
The first human TBI study of S100B’s value as a serum
biomarker of brain injury assessment was published by
Ingebrigtsen and coworkers in 1995 [75], although increased
S100B levels in cerebrospinal fluid (CSF) following various
neurological disorders had been previously described in pa-
tients by Sindic et al. in 1982 [165]. Later on, S100B was
shown to be sensitive enough to detect and assess different
traumatic intracranial lesions, including cerebral contusions
[144], subdural hematomas and traumatic subarachnoid hem-
orrhages [152], as well as epidural hematomas [189].
While several reviews currently exist, highlighting the role
of S100B in both mild [193] and moderate-to-severe TBI
[104], new aspects have evolved in this field such as the find-
ing of S100B transportation through the newly discovered
glymphatic system [141], implementat ion of the
Scandinavian guidelines for TBI incorporating S100B [194]
and improved kinetic modeling of S100B release from the
injured brain [42].
This review aims to give the clinician a comprehensive
overview of the utilities of S100B in the assessment of brain
injury and may thus be used as a guide to interpret serum
S100B samples in the treatment of both mild and moderate
to severe TBI patients.
The protein S100B
The protein S100 was originally isolated from bovine brain
almost 50 years ago and got the name from its 100% solubility
in a saturated ammonium sulfate solution [108]. S100 is a
relatively small protein, 9–14 kDa, present physiologically
mainly as different homodimers [36]. It belongs to a family
of intracellular, calcium-binding proteins predominantly pres-
ent in mature, perivascular astrocytes, but is also present to
some extent in other cells in the central nervous system
(CNS), including oligodendrocytes, neural progenitor cells
and certain neuronal populations [39, 172]. In the CNS, the
protein exists mainly as the homodimer S100BB or heterodi-
mer S100AB [58, 76]. Together, these proteins make up the
levels of what is usually referred to clinically as BS100B^ (or
sometimes BS100B Total^). Several other proteins of the S100
family exist, whose functions have been previously described
in several review articles [37, 38, 84].
Ideally, a biomarker of brain injury should fulfill the fol-
lowing criteria according to prominent authors in the field [84,
130] (Table 1). Currently, no biomarker fulfills all the criteria,
but as S100B is the most studied, we are learning how to
interpret and assess it in different situations, thus minimizing
and avoiding potential limitations.
Functions of S100B
S100B has several properties, previously reviewed [36–38,
49, 106, 196]. Intracellularly, S100B is a normal part of calci-
um hemostasis, thereby transferring signals from second mes-
sengers [64]. S100B is also involved in cell differentiation and
cell cycle progression [158], and it has been shown to inhibit
apoptosis if applied in experimental conditions [25].
Extracellularly, in both normal physiology and during trau-
matic conditions, administered S100B promotes neurogenesis
[1, 57] and neuronal plasticity [103, 120], performs neuro-
modulating actions and enhances processes involved in mem-
ory and learning [43, 83].
However, the effect and physiological functions of S100B
have been shown to be concentration dependent, where lower
concentrations (nanomolar levels) are beneficial and higher
concentrations (micromolar levels) are correlated to harmful
effects [154, 196]. Escalating extracellular levels of S100B
have been shown to result in neuronal dysfunction or cell
death because of an inflammatory response that stimulates
astrocytes and microglia to recruit and produce proinflamma-
tory cytokines with a subsequent increase of the extracellular
levels of calcium and activation of nitric oxide, with harmful
effects [69, 89].
The different effects of S100B have been suggested to de-
pend on the Receptor for Advanced Glycation End-products
(RAGE), which is upregulated by S100B levels and may
cause proinflammatory gene activation [38], although much
is still unknown about how S100B exerts its biochemical
properties.
Table 1 Suggested properties for biomarkers in traumatic brain injury
Demonstrate a high sensitivity and specificity for brain injury
Exhibit a passive release from the central nervous system (CNS) without
any stimulated active release
Lack specific effects on CNS cells interfering with the initial injury
Useful to stratify patients by severity of injury and provide information
about injury mechanisms
Have a rapid appearance in accessible biological fluids and an unlimited
passage from the brain
Have well-defined bio-kinetic properties and monitor progress of disease
and response to treatment
Predict functional outcome
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Release and elimination of S100B
In vitro studies reveal that astrocytes, when affected by trauma
or metabolic distress [47], will release stored S100B, which
has been measured extracellularly as fast as 15 s after a lesion
is established [200]. The S100B mRNA concentration, as a
sign of ongoing intracellular synthesis of the protein, will also
increase shortly after injury [68]; thus, the concentrations
measured in blood are from both secreted and newly synthe-
sized origins. However, looking at the volumes of synthesized
mRNA, the majority of the measured S100B in bodily fluids
seems to come from dead or dying cerebral tissue.
It is known that the concentration of S100B in the CSF
could be up to 100× higher than in serum [137]. A majority
of the S100B is presumably released directly from the CSF to
serum through the arachnoid villi, as the ratio between the
CSF:serum of S100B is correlated, especially early after the
TBI [51]. When the patient suffers from TBI, the blood-brain
barrier (BBB) is disrupted, causing a leakage of proteins from
the CSF with subsequent cerebral deterioration and edema
formation [100]. The ratio of albumin between CSF:serum
(QA) is often used to quantify the degree of BBB disruption
[184]. Some authors claim that S100B is released into the
serum through the disrupted BBB [80, 81, 99]; thus, it is a
good marker of BBB permeability [20, 97]. However, the
studies supporting S100B as a marker solely for BBB integrity
are limited in sample size, use osmotic or chemo-therapy in
non-TBI patients to disrupt the BBB and are not focused on
the complex BBB disruption present following traumatic con-
ditions. Studies that focus on TBI patients do not show any
correlation between a disrupted BBB, using QA, and the peak
serum levels of S100B [14] or by using a ratio of the CSF and
serum S100B compared to QA [87], hence indicating a better
correlation between actual injury and S100B levels and not to
the degree of BBB disruption.
Furthermore, a route between the para-arterial influx, inter-
stitial fluid of the brain, cerebrospinal fluid and venous out-
flow has recently been discovered, entitled the glymphatic
system because of the connection between glial cells and
aquaporin-4-dependent paravascular pathways (mimicking a
lymphatic drainage from the brain) [71]. It has recently been
shown that this system probably plays a very important role in
the outflow of S100B from the brain, which could explain the
discrepancies found in TBI studies looking at correlations
between BBB integrity and S100B release [141]. Recent find-
ings in animal models suggest that S100B, as well as the
biomarkers neuron-specific enolase (NSE) and glial fibrillary
acidic protein (GFAP), are released through the glymphatic
drainage, independent of BBB permeability [141]. If this is
confirmed, it constitutes several challenges to the interpreta-
tion of the serum levels of protein biomarkers in humans.
First, the recently discovered glymphatic system is, so far,
impossible to monitor in vivo in humans, and no surrogate
marker to assess the glymphatic system exists today. This will
make it difficult to evaluate whether the glymphatic system
plays the same role in humans as in animal brain biomarker
release. Second, in studies from the Nedergaard group that
discovered the glymphatic system [70, 71], the aquaporin-4-
containing podocytes of perivascular astrocytes depolarize for
up to 4 weeks following experimental traumatic brain injury,
resulting in a disrupted glymphatic clearance. In theory, this
might also affect the biomarker release from the injured brain
in humans. Third, the glymphatic drainage has been shown to
be affected if CSF is drained by pharmaceutical compounds as
well as if sleep is affected. Draining the CSF and sedating
patients (possibly similar to sleep) are two common treatment
modalities in the NICU for severely brain injured patients to
maintain adequate intracranial pressure. Thus, different ac-
tions in the NICU will have an effect on the release of
S100B in serum.
Systemically, S100B has been shown to be excreted and
eliminated 100% through the kidneys [195]. Patients with
renal failure have higher baseline S100B levels compared to
healthy controls [107], which should be taken into consider-
ation when assessing S100B in these patients. However, the
mild to moderate kidney impairment often seen in trauma
patients has not been shown to significantly affect S100B
levels in serum [79].
In summary, S100B is released from the CSF to serum, but
this drainage could be affected by the glymphatic clearance as
well as the BBB permeability. Therefore, although it is seem-
ingly passive, it may in theory be altered by different factors.
Extracranial sources of S100B
There are several known extracerebral sources of protein
S100B, such as Langerhan’s cells, adipocytes, epithelial cells,
cardiac and skeletal muscle cells, and chondrocytes [58].
According to researchers involved in the Human Protein
Atlas, S100B mRNA is only 1.44 times more expressed in
the cerebral cortex compared to adipose tissue, the second
most common tissue containing S100B [166]. This could be
compared with GFAP mRNA, which is 374.81 times more
common in the brain compared to adipose tissue, the second
most common source for that protein as well. Notably, GFAP-
brain specificity is only Bbeaten^ by oligodendrocytic myelin
paranodal and inner loop protein (OPALIN), with mRNA
541.99 times more common in the brain than in any other
analyzed tissue [166]. Patients who suffer from trauma, pre-
senting multiple injuries to the thorax, extremities and abdom-
inal organs without any identified damages to the central ner-
vous system, have been shown to exhibit elevated S100B
concentrations in serum [7, 138, 155, 190]. However, S100B
released from an extracerebral origin appears to have a faster
clearance than S100B released from the CNS [33, 134, 157],
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while some authors suggest a very limited contribution from
extracranial sources [139]. In our group, we have also seen
that extracranial trauma contributes independently to in-
creased serum levels of S100B [182]. When conducting a
sliding window over time, we found that the early peak and
values <12 h after trauma are poorly correlated to outcome
[180]. After 12 h there is an increase in relations to outcome,
which peaks around the end of day 1 [179], which is congru-
ent with the kinetic modeling where the main injury peak is
found at 27 h [42]. The early or near immediate peak is as-
sumed to be of extra-cranial origin as it is correlated to multi-
trauma and, in contrast to the gamma-variate kinetics of the
main peak, appears to follow a first-order kinetic with rapid
decay [42].
In summary, while possible extracranial sources should be
taken into consideration when assessing TBI patients [135],
repeated sampling after 12 h should exclude several of these
confounding factors. This, however, has implications for the
use of S100B as an early warning sign in mild TBI.
Half-life of S100B
It is difficult to assess the half-life of S100B in serum after TBI
since there will be a continuous release of the protein from the
damaged brain and perhaps a contribution from the CSF due
to a disruption of the BBB [81], outflow through the
glymphatic system [141] and ongoing cerebral synthesis
and/or active secretion [47, 68]. The half-life of S100B has
been shown to be in the range of 60 to 120min in patients with
TBI [73, 77] and 90 min in patients suffering from malignant
melanoma [48]. Another more controlled method makes it as
short as 25 min [79], calculated from patients undergoing
coronary artery bypass grafting not suffering from any evident
brain injury.
In aggregate, the net amount of S100B in serum will thus
be the summed effect of the rate of influx and the rate of
elimination. As the serum half-life of S100B is short, an ex-
tended elevation of S100B indicates an ongoing influx. We
have recently shown this to be well fitted to the gamma variate
function [42] in patients with TBI. The peak and area under
the curve of the increase appear to correspond to the extent of
the damage sustained [179].
Assays to analyze S100B
There are several available assay kits to measure S100B that
are used in clinics and laboratories. An advantage of S100B is
that it is stable and relatively unaffected by storing, changes in
temperature and freeze-thaw cycles [146], which greatly facil-
itate the handling of the protein and reliability of the analyses.
Another advantage with S100B is that it is not affected by
hemolysis in the sample [13], making it a robust sample to
use in the acute setting. ELISA has become the gold standard
for measuring S100B in laboratories, and kits are commercial-
ly available from several different manufacturers (Sangtec,
Italy; CanAG Diagnostics, Sweden; Syn X Pharma Inc.
Nanogen, USA, to name a few). Unfortunately, ELISA assays
take 4–6 h to run and generally present higher inter- and intra-
coefficients of variation (CVs) compared to clinical assays,
resulting in a worse functional sensitivity of the devices
[167], making them difficult to use in the clinic.
In clinical settings, the two most frequently used systems
are the quantitative automated luminometric immunoassay
LIAISON-mat S100 system (Diasorin, Sangtec, Italy) and
the electrochemiluminescence immunoassay (Elecsys
S100B®; Roche Diagnostics, Penzberg, Germany). The
LIAISON system was primarily designed to detect and screen
for S100B in malignant melanoma and other tumors and is
thus not designed for quick analyses [116]. The Elecsys sys-
tem and the new automated Cobas® system from Roche
Diagnostics are increasing in popularity since they take only
18min to run a serum sample, making it more suitable for TBI
and possible for both emergency room (ER) and NICU use
[167].
New point-of-care bedside devices are being developed
[122] to be able to swiftly detect elevations of S100B. These
kits could be deployed on the battlefield or in ambulances to
quickly assess S100B levels above certain thresholds using
bio-sensors.
Clinical use of S100B
A number of review articles have thoroughly analyzed differ-
ent aspects of the clinical utilities of S100B [10, 19, 44, 84, 88,
91, 104, 159].
S100B from extracranial sources has long been used to
monitor the advancement and evaluate the efficacy of therapy
of melanocytic tumors [40, 82, 168]. As an interesting note,
persons with darker skin have higher serum levels of S100B
(median 0.14 μg/l) as compared to persons with brighter skin
(median 0.07μg/l) [15], presumably due to a higher metabolic
activity in melanocytes in the former group [6]. This might be
of importance when calculating outcome from TBI in patients
with darker skin, as higher serum levels may be falsely
interpreted as elevated, resulting in an unnecessary CT scan
in mild TBI.
A clinical role has also been shown for different cerebral
conditions, including stroke [23, 45], global ischemia [115,
195], neurodegenerative disorders such as MS and
Alzheimer’s disease [154], spontaneous subarachnoid hemor-
rhage [109, 123, 156, 175] and cerebral vasospasm [123].
Nevertheless, it is in the field of TBI where it has been mostly
studied.
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All traumatic cerebral injuries have been shown to increase
S100B in serum, but focal injuries, such as cerebral contusions
and subdural hematomas, present higher levels as compared to
diffuse injuries [67], and contusion volumes have been direct-
ly correlated to serum levels of S100B [140, 144]. This further
stresses that the amount of tissue affected is much more im-
portant than the exact spatial location when assessing brain
injury using S100B. Thus, the importance of combining
S100B with proper imaging is necessary to visualize anatom-
ical localization of the injury.
However, S100B has been shown to be able to stratify
patients by injury severity, as can be seen in studies showing
low S100B levels in mild TBI (GCS14-15) and escalating
levels in moderate (GCS9-13) and severe (GCS3-8) TBI
[67, 152]. The most common CT classification of injury is
the Marshall CT classification [101], where S100B has been
shown to increase in the focal, more severe, lesions compared
to more diffuse injuries [90, 140]. Other classifications of
injury include the Rotterdam CT score [98] and Stockholm
CT score [117], where an increasing sum is associated with a
more unfavorable outcome, also showing a correlation to in-
creased serum levels of S100B as the injury becomes more
severe [179]. More novel techniques for image outcome fol-
lowing traumatic brain injury exist; one of them is functional
MRI, where levels of S100B in serum have been shown to
correlate to the extent of disrupted connectivity in the default
mode networks [183].
S100B to screen for intracranial pathology in adult,
mild TBI patients
The vast majority (estimated up to 95%) of all TBI cases
present as mild, defined as a Glasgow Coma Scale (GCS)
score of 14–15 [29], and are common patients in the emergen-
cy room (ER). The physician in the ER is often presented with
the challenge of how to assess these patients as they are often
intoxicated; up to 50% of mild TBI patients suffer from alco-
hol intoxication [125] and could have problems remembering
what exactly happened as well as whether any post-traumatic
symptoms occurred, something that could be difficult even for
the sober.
Moreover, some of these patients may develop intracranial
hematomas in need of surgical evacuation or intracranial mon-
itoring. To detect these lesions, a computerized tomography
(CT) scan of the brain is the preferred radiological choice
[170]. However, these should be minimized as they are ac-
companied by a significant dose of radiation and therefore a
slightly increased risk of cancer, and they may even have an
effect on cognitive functions later in life [24, 59]. To deter-
mine which patients to scan, specific guidelines have been
presented, such as the Canadian CT rule [173], the NEXUS-
II [111] and the Scandinavian CT guidelines from 2000 [74].
Using the Scandinavian guidelines from 2000, the sensitivity
to detect an intracranial lesion is 96%, but the specificity only
53%, similar to the other guidelines [171]. Therefore, even if
few lesions are missed using CT scanning, many unnecessary
CT scans are performed with excess radiation and costs as a
consequence. Furthermore, scanning intoxicated patients may
require sedation and intubation, which could be potentially
harmful for the patient.
The introduction of S100B sampling in the ER has intro-
duced a way to potentially screen which patients are in need of
a CTscan. Ameta-analysis onmild TBI and S100B, including
2,466 patients from 12 articles, states that the pooled negative
predictive value (NPV) was more than 99% (CI 98%–100%)
with a sensitivity of 97% in S100B detecting CT-visual brain
pathology, using 0.10 μg/l as the cutoff [193]. This sensitivity
and NPV make S100B superior to D-dimer, for example, in
detecting pulmonary embolism and deep vein thrombosis
(NPV: 92%) [198] and troponin-T (NPV: 96%) [60] in detect-
ing myocardial infarction. The authors, however, do stress the
importance of acquiring the sample early, within 6 h, after a
mild TBI (due to the short half-life) and not using it in patients
with extracranial injuries, since these patients will present
S100B from extracranial sources and would thus lower the
specificity for intracranial lesions [193].
This meta-analysis formed the foundation for the new
Scandinavian CT guidelines for mild and moderate TBI from
2013 [192]. These guidelines today assist physicians and per-
sonnel in the ERs in several Scandinavian hospitals to better
determine which mild TBI patients are in need of a head CT
scan by acquiring a serum sample of S100B. If the concentra-
tion is less than 0.10 μg/l within 6 h after trauma and the
patient is suffering from a mild TBI without extracranial trau-
ma and other risk factors, not performing a head CT scan
could be considered [192]. In theory, it is estimated that this
could reduce the number of unnecessary CT investigations by
about a third in the emergency departments with more effec-
tive resource allocation.
A risk that must be avoided and has been seen locally is to
use S100B indiscriminately as a general screening tool to
identify those in need of a CT, not considering the clinical
indication and possible extra-cranial trauma-related peaks, as
this may increase the number of CTs done instead of decreas-
ing it. One should bear in mind though that not all cerebral
pathology is visible on CT scans [93]; some lesions appear
only on magnetic resonance imaging (MRI) or the more ac-
curate diffuse tensor imaging (DTI). Authors are suggesting
that some of these Bfalse-positive^ S100B levels might indi-
cate lesions only seen on MRI [72], and as more sensitive
radiological techniques become available, perhaps the speci-
ficity for S100B to detect intracranial lesions will increase.
Some of the CT scans in studies included in the meta-
analysis that formed the basis of the Scandinavian guidelines
[193] could also have been performed too early (within
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90 min) and thus may have missed the natural progression of
cerebral contusions [199]. An inherent risk we have noted
when using S100B to identify patients with mild TBI requir-
ing a CT scan in the ER is if instead it is used as triage prior to
clinical evaluation. This will recruit an unintended cohort of
patients often with trauma-related S100B levels, increasing
the risk of false-positive results and the risk of unnecessary
CT scans. As mentioned, another factor that may cause
Bfalsely^ increased S100B levels is darker skin [15], some-
thing that may need to be further evaluated and possibly in-
corporated into current guidelines.
Theoretically and shortly after injury, the sensitivity of
identifying a brain injury requiring a CT scan using S100B
with a relatively low cutoff (i.e., 0.1 μg/l) is high, as a sub-
stantial amount of S100B will be released from the brain, as
well as from potential extracranial sources [182]; however,
this specific cutoff also results in a low specificity of intracra-
nial injury if sampled too early. As time progresses, the short
serum half-life of S100B will lead to a high wash-out of
S100B, especially if there is no ongoing intracranial release
or progressing injury.
A recent retrospective external validation of the new
Scandinavian CT guidelines from 2013 was published last year
[194], where the authors noticed that in a cohort of 662 patients,
the guidelines had a sensitivity of 97% and a specificity of 34%,
and this resulted in a CT reduction of 32% if applied [194]. One
patient had an S100B level <0.1 μg/l and a small cortical con-
tusion, but this patient presented with a mild TBI and perhaps
would not have had a CT performed if other guidelines had been
followed. Furthermore, the patient fully recovered shortly after
injury. Another recent report from Calcagnile and co-workers
revealed that the implementation of S100B to screen for intra-
cranial lesions led to a cost reduction of 39€ per patient in their
department, with theoretical savings of up to 70€ per patient if
implemented correctly according to the guidelines [27].
In summary, we conclude that, given the above caveats
concerning specificity, sensitivity and usage, the current sug-
gested cutoff levels appear to provide a reasonable and clini-
cally useful tool to detect CT visible intracranial pathology in
mild TBI patients. Given the introduction of the Scandinavian
guidelines, the effects of this transition will however need to
be monitored for safety.
Potentially missed lesions in mild TBI because
of the 2013 Scandinavian guidelines
Recently, a new meta-analysis was published including n =
3,893 patients [63], suggesting higher cutoff levels (0.16–
0.20 μg/l) to improve the specificity (to 50.69%) to detect
CT-visible intracranial pathology. However, as we approach
6 h after trauma, the lower cutoff of 0.1 μg/l is probably better
as it appears to assure an acceptable level to detect injury. By
choosing a higher cutoff, we increase the risk of missing epi-
dural hematomas, for example, which often present with only
marginally elevated S100B levels [189]. While Undén and co-
workers did not find any patient with EDH to have an S100B
lower than 0.14 μg/l [189], others have detected S100B levels
well below 0.1 μg/l in these patients [5, 202]. However, in these
studies the Scandinavian guidelines were not implemented, and
the exact time after trauma was unknown, thus confounding
interpretation of these results. As the cerebral parenchyma is
only marginally affected in the early stages of a progressing
EDH, lower brain biomarker levels are expected. Presumably,
some of the early S100B contribution in these cases could come
from associated cranial fractures [131].
That even 0.1 μg/l of S100B might miss patients with pos-
itive CT findings was highlighted in the external validations of
the Scandinavian CT guidelines [194]; however, these guide-
lines appear to have a similar capability to discriminate those
in need of CT scans as other CT guidelines for mild TBI used
worldwide [171].
In summary, the S100B cutoff to detect intracranial pathol-
ogy in mild TBI should not be used in isolation, but as an
integrated part of the assessment including clinical evaluation
in order not to miss potentially harmful lesions, in concor-
dance with the Scandinavian guidelines.
S100B to assess sports-related brain injuries
Another field where mild, and often repetitive, TBI is com-
mon is in contact sports. Here, the unreported incidence may
be higher than 600 per 100,000 people per year compared to
the 200 per 100,000 reported incidence [29]. While a minimal
number of these accidents results in verifiable cerebral lesions
that need extensive medical attention, several athletes suffer
from post-concussion-like symptoms (including chronic trau-
matic encephalopathy, CTE [126]) affecting somatic, affective
and cognitive capabilities, sometimes persistent, preventing
return to work and other daily activities [29].
Several studies have highlighted the role of S100B as a
marker of brain injury severity in this group that was recently
reviewed [129, 161], where S100B levels, among other things,
were correlated to the ability to return to work [174]. Again, it
should also be noted that S100B is increased in athletes without
any obvious head injury, such as swimmers and marathon run-
ners [161], which could be due to extracranial release,
representing a confounder especially in mild head injuries
where a limited amount of brain parenchymamight be affected.
Clinical use of S100B in children
Perhaps the area that may best benefit from a surrogate marker
to rule out unnecessary CT scanning is the pediatric
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population, as radiation emanating from CTs has been shown
to be particularly harmful in this group [24, 59]. In fact, for a
1-year-old child, studies estimate the risk of developing a le-
thal malignancy from a single CT of the brain to be as high as
1:1500 compared with 1:5000 for a 10-year-old child [24].
Additionally, S100B is neurotrophic, and levels in serum are
generally increased in the pediatric population with a growing
CNS, thus presenting great variation of normal reference
levels up to 15 years of age [8, 21, 30]. While higher cutoffs
have been suggested for 0–24 month olds (0.35–0.23 μg/l)
[22], the Scandinavian Neurotrauma Committee recently
found it presently not possible to implement S100B using a
similar cutoff approach as used in adults to detect patients
eligible for CT scanning in children [9]. More knowledge of
age-dependent normal values need to be evaluated before
S100B can be used as a safe guide for decision making
concerning CTscanning in children. Moreover, S100B is easy
to obtain via both capillary and urinary samples, both
representing ways to detect the protein [8, 18]. Not having
to use venipuncture could be preferable for children.
However, the utility of urinary S100B levels warrants further
research and evaluation.
In more severe pediatric TBI cases, temporal profiles of
subsequent samples of S100B in serum, referred to as a tra-
jectory analysis, with increasing serum levels have a higher
risk of unfavorable outcome compared to patients with subse-
quent serum concentrations in steady decline [17]. Thus,
S100B may represent a similar surrogate marker of injury
for outcome prediction and monitoring to detect secondary
injuries as in the adult population. Other areas where S100B
might provide important information about cerebral injuries
are in the assessment of preterm newborns [163] and follow-
ing hypoxic-ischemic injuries [53], recently reviewed
respectively.
In summary, while S100B could benefit the pediatric pop-
ulation in the assessment of brain injury, more research is
necessary before possible guideline implementation.
S100B and outcome prediction in moderate-to-severe
TBI in adults
Several reviews have analyzed how S100B may be utilized in
moderate and severe TBI patients [16, 49, 66, 86, 92, 96, 130,
147, 162, 176, 186].
As severely brain injured patients enter the emergency de-
partment and the intensive care unit, they are often sedated
and/or intubated making neurological assessments problemat-
ic. While CT examinations aid in the diagnosis and surgical
planning, it is often difficult to fully predict the outcome of
these patients [114]. Thus, a marker of brain tissue fate that
may guide initial treatment and resources for patients in most
urgent need in this critical phase is highly sought.
One of the latest reviews of S100B from 2013 includes a
meta-analysis of 39 studies, including a total of 1,862 patients
[104]. The authors found that serum levels between 2.16 μg/l
and 14.0 μg/l predicted an unfavorable outcome, defined as a
Glasgow Outcome Score (GOS) of 1 (death), 2 (vegetative
state) or 3 (severe disability), and similar serum levels in six
of the included studies were associated with mortality [104].
This wide concentration range is a huge problem for standard-
ization and accurate cutoffs for outcome prediction. One of the
major reasons for this, which is also discussed by the authors
of the review, is the difference in sampling time in the studies.
The optimal time for collecting S100B to predict outcome
after trauma in moderate-to-severe TBI has been a matter of
intense discussions. In several studies, the initial sample of
serum S100B after trauma is considered the most important
for outcome prediction [77, 136, 147, 152]. Later time frames
have also been suggested to have clinical significance, ranging
from within 6 h [201], 6 to 12 h [147], within 12 h [112], after
12 h [145], 24 h [50], within 42 to 79 h [67], within 48 h [134,
197], 72 h [113] and finally up to >84 h after trauma [134].
Thus, the serum concentration of S100B itself is of limited use
to predict outcome if the time that has lapsed since the trauma
is unknown.
Our group has shown, in a cohort of 265 NICU TBI pa-
tients, that the initial serum sample of S100B at admission has
lower predicted accuracy toward outcome compared to later
samples acquired approximately 24 h after admission [180].
The predictive accuracy of S100B is in fact 2–3× higher than
age, pupil responsiveness or GCS at admission separately, all
being known independent outcome predictors of injury sug-
gested by the IMPACT (International Mission for Prognosis
and Analysis of Clinical Trials in TBI) study group [114]. In a
more recent study from our group, including the largest single-
center patient cohort to date (n = 417 NICU TBI patients), the
best outcome prediction for S100B occurred at about 30 h
after reported trauma, with pseudo-explained variance of
about 25% [179]. This latter predictive value is in congruence
with our findings of a fitted kinetic model designed by our
group, where the peak was found to be at 27 h [42]. In Fig. 1,
we present a schematic overview of how we interpret the
temporal release patterns of S100B and sources involved.
The reason for the weak initial correlation between early
S100B and outcome appears to be the result of the extracranial
contribution of S100B Bmasking^ the intracranial release. At
30 h, patients with a long-term GOS 1 (death) had a median
S100B of 1 μg/l, GOS 3 (severe disability) 0.5 μg/l, GOS 4
(moderate disability) 0.3 μg/l and GOS 5 (good recovery)
0.25 μg/l, while it was not possible to detect specific serum
levels significant for different GOS scores at admission [179].
The capabilities of S100B to predict outcome have led
some authors to conclude that S100B could be used as a
marker of brain death following injury [41, 164]. However,
we believe that there are several reasons why this is potentially
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dangerous and should be avoided. First, due to its low specific-
ity of brain injury, other reasons for S100B increases should
always be explored. We have for instance seen extreme in-
creases of S100B in serum [135] in a patient with mild TBI
and malignant melanoma. Second, the S100B levels suggested
by authors promoting S100B as a marker for brain death diag-
nostics (0.372 μg/l the first 24 h) are levels in patients that we
repeatedly have seen return to a favorable outcome 12 months
after injury [180]. Third, we hypothesize that S100B needs
perfusion through the affected tissue for it to be released to
the blood and that this process will be non-existent in brain
dead patients, making S100B levels unreliable. Our clinical
experience, having followed S100B in close to 3,000 NICU
patients (both TBI and subarachnoid hemorrhage patients), is
that levels prior to verified brain death are highly variable.
Undén and co-workers measured S100B during this condition
and noticed that without adequate circulation (CPP, cerebral
perfusion pressure) to the brain, because of a high ICP, consid-
erably lower amounts of S100B will be released [191]. Hence,
this is also probablywhy S100B is a poor biomarker in the early
stages of thrombo-embolic stroke [45]. Our clinical experience
also leads us to suspect that sharp S100B peaks after strokemay
represent a reperfusion washout; however, this needs to be con-
firmed. Thus, S100B should not be considered as a tool to
identify brain death or support decision-making concerning
withholding of treatments in severe TBI cases.
In summary, after accounting for its limitations concerning
the low specificity of early samples, S100B appears to be an
important and useful predictor of functional outcome in
moderate-to-severe TBI, stressing however that no compound
prediction models in TBI to date are accurate enough to sup-
port end of life decisions per se. Instead, S100B should help
physicians prioritize resources to patients and may be part of
future patient stratification strategies.
S100B as a monitoring marker of ongoing injury
in adults
Studies that subsequently sampled S100B during the hospital
stay described scenarios where the levels of S100B continue
to increase following TBI [85, 134], and these Bclimbers^
have been shown to present an unfavorable outcome [177].
Moreover, patients without a steady decline of S100B in CSF
and serum have been shown to present with worse outcome
[51, 121, 149]. Serial S100B has even been suggested to out-
perform repeated radiological examinations to predict out-
come [52]. Thus, there is a clinical interest in studying the
kinetics of S100B following traumatic brain injury.
As the half-life of S100B in serum is short, a recent serum
increase would theoretically correspond to a recent cerebral
injury. We carefully mapped the kinetics of S100B in NICU
TBI patients and noted that even small changes in time dra-
matically alter S100B levels and that the peak in the serum
S100B concentration with seemingly unaffected wash-out is
around 27 h after reported trauma [42]. Moreover, deviations
from this normal curve as well as secondary peaks of S100B
(Fig. 1) would presumably be a result of ongoing or new
cerebral lesions.
Raabe and co-workers took daily S100B samples from
their patients and found that a secondary increase of S100B
>0.5 μg/l significantly correlated to the development of a se-
vere secondary injury, such as a cerebral infarction or hema-
toma progression [148]. Moreover, they found that this sec-
ondary increase of S100B influenced treatment and diagnosis
in 21% of the cases. An additional study by Undén et al.
revealed that increased levels of S100B were correlated with
secondary neurological complications [188], but the authors
could not demonstrate a robus correlation between the second-
ary peaks and these complications, or that these complications
Fig. 1 Schematic overview of S100B release to serum. Schematic
overview of the S100B release following severe TBI. Initially, there
will be a great release of S100B from extracranial tissue to the serum
(dotted, gray line), which will have a rapid wash-out the first hours after
injury. While the cerebral release is more prolonged and shaped as a
gamma function, as suggested by Ercole et al. 2016 (black line), it will
initially be Bmasked^ by these extracranial contributions. Our black line
illustrates an Buneventful^ release of S100B in a patient suffering from
severe TBI; however, patients may suffer from subsequent injuries
resulting in Bsecondary peaks^ of S100B (dashed, gray line)
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were associated with long-term outcome.We noted in a cohort
of 250 NICU TBI patients that a secondary increase as subtle
as 0.05μg/l in patients sampled twice daily had a sensitivity of
80% and a specificity of 89% to detect secondary radiological
pathological findings [181]. Moreover, these secondary in-
creases in S100B were significant predictors of unfavorable
outcome. In Fig. 2, we illustrate how serial sampling of S100B
detected a secondary peak of S100B, which correlated to the
development of a right temporal infarction, a deterioration not
detected using ICP monitoring. Our findings are similar to
those of other TBI cohorts; several studies have shown a cor-
relation between neurological deterioration and a secondary
increase of S100B during the NICU stay, suggesting it to be a
useful therapeutic tool closely related to pathophysiological
mechanisms in TBI [35, 65, 90].
We have shown that serum S100B has definable kinetic
properties following TBI [42]. We are of the conviction that
kinetic properties are a key strength of S100B as compared to
certain other markers, such as GFAP, while GFAP, presumably
because of its higher brain specificity, may be advantageous
compared to S100B in screening mild TBI patients who re-
quire a CT in the ER [131]; the half-life of GFAP in serum is
significantly longer than that of S100B (25 min vs. <48 h) [34,
79]. Thus, S100B should theoretically wash out quickly from
the system if no S100B is contributed from an ongoing or
evolving cerebral lesion, as it contains so much more S100B
compared to other tissues. This is the primary reasons why it is
difficult to establish outcome thresholds for S100B levels, as
they will change rapidly in the serum during the first days
following TBI [179], but at the same time it is this dynamic
information content that strengthens their potential role as a
monitoring marker and supports serial sampling [148, 181].
Therefore, using kinetic modeling, we defined the gamma-
variate curve that S100B is expected to follow [42]. This al-
lows for reliably estimating the projected peak from any time
point given that the time of trauma is known and provided that
no secondary insults initiate a new release sequence.
In summary, these findings strengthen the role of S100B as a
laboratory test for monitoring patients admitted to the NICU
with frequent sampling preferable to detect potential injury pro-
gression that may prompt diagnostic and therapeutic actions.
S100B as a surrogate marker for treatment efficacy
Several groups, including ours, have found a correlation be-
tween ICP and serum S100B levels [14, 62, 124, 134, 181].
Since ICP is currently the most widely used surrogate marker
to assess intracranial conditions, it supports the theory of
S100B as a marker to guide treatment in the NICU.
Preclinically, S100B has been shown to be useful in deter-
mining the success of ischemic stroke treatment in rabbits
[203]. Clinically, S100B has been used as a marker to validate
the treatment effect in TBI patients between hypertonic saline-
dextran (HSD) and normal saline, where the HSD group pre-
sented lower levels, presumably indicating a less affected brain
parenchyma [11]. During procedures such as hypothermia treat-
ment following cardiac arrest [110], carotid endarterectomy [3]
and cardiac surgery [187] and hyperbaric oxygen therapy fol-
lowing TBI [178], S100B levels in serummay be used to detect
and treat any ongoing cerebral injury. Moreover, in clinical
depression, S100B has been shown to be able to predict treat-
ment response [4] and extra-cranially, as mentioned, to follow
the treatment of malignant melanoma [40].
Currently, there are no pharmaceutical treatments to date that
specifically target the underlying pathophysiology in TBI as all
large placebo controlled randomized control trials have failed to
show significant treatment efficacy [61], including, e.g.,
methyl-prednisolone [150], progesterone [205] and erythropoi-
etin [119]. One of the reasons these trials have failed is believed
to be a lack of methods to validate the therapeutic effect and
instead focus predominantly on late outcomes, which may be
influenced by a multitude of factors, thus introducing noise and
possibly drowning possible treatment effects. In a recent, small-
er study of erythropoietin in human TBI, S100B was used as a
proxy of treatment effect with decreasing levels seen in patients
treated with the drug vs. placebo, thus suggesting a lesser extent
of tissue injury [94].
In summary, by introducing serum biomarkers such as
S100B in future pharmaceutical trials, as well as better radio-
logical markers [28], it may be possible to better monitor
surrogate markers of effect in relation to specific pharmaco-
logical treatments.
Other protein biomarkers of brain tissue fate
There are several other theoretically brain-specific proteins
that are used as biomarkers to assess brain injury [206].
Here, we focus briefly on some of the most studied in the
context of S100B.
Neuron-specific enolase (NSE)
The second most published biomarker of brain injury is NSE.
NSE is an iso-enzyme of enolase located primarily in the
cytoplasm of neurons, involved in glycolysis by transforming
2-phosphoglycerate into phosphoenolpyruvate. When re-
leased in blood, it has a half-life of approximately 24 h in
patients not affected by brain injury, to 48 h in patients suffer-
ing from brain injury [73, 78, 160]. Recent reviews and meta-
analyses highlight its properties as an independent marker of
functional outcome and mortality [31], albeit it being inferior
to S100B [105]. The main limitation of NSE is its presence in
red blood cells, causing problems in serum analyses in the
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case of hemolysis [46]. While modern techniques may try to
adjust for this [185], hemolysis will often cause Bfalse
increases^ of NSE making it difficult to assess in the emer-
gency and NICU setting. In our group, we recently compared
S100B and NSE and found that S100B was a better outcome
predictor overall, with NSE only predicting mortality [179].
Importantly, despite NSE originating from neurons as op-
posed to astrocytes, a high covariance between S100B and
NSE was seen. This also explains why it did not provide any
additional information over S100B toward outcome predic-
tion. Moreover, while an extracranial contribution from
multitrauma was evident for S100B, this normalized within
12 h. However, the correlation of NSE levels to multitrauma
extends past 72 h. This could theoretically be due to its longer
half-life, but also a contribution of NSE from trauma-related
hematomas is possible [179].
Glial fibrillary acidic protein (GFAP)
GFAP is an intermediate filament cytoskeleton protein primar-
ily found in astrocytes; thus, it shares an origin with S100B.
However, compared to S100B, GFAP is more brain specific
[133, 166], which is probably why one study found a greater
specificity in detecting CT-verifiable lesions in mild TBI pa-
tients compared to S100B in the presence of extracranial in-
jury (5% vs. 55%) [131].While kinetic studies have revealed a
prolonged release and higher levels in mild TBI patients with
CT lesions [127], no definitive results exist on the in vivo half-
life. In vitro studies put the half-life of GFAP somewhere
between 16–144 h for different subunits [32, 151, 169], while
one clinical study suggested it is <48 h in serum [34].
Although GFAP has been shown to be elevated in patients
needing neurosurgical intervention [127], it has not been as
Fig. 2 S100B monitoring of a TBI patient. The patient was monitored
with subsequent sampling of S100B (twice per day, y-axis μg/l of S100B
and x-axis days after trauma) illustrating an initial decline the first days
following trauma approaching baseline levels. However, at day 16–18
(bar), there is a secondary peak of S100B that correlates to the
development of a right temporal infarction as seen on computerized
tomography (arrows)
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extensively studied as a monitoring marker as S100B. For
outcome prediction in moderate-to-severe TBI, GFAP has
been shown to exhibit similar outcome predictive capabilities
as S100B, and a combination of the twomarkers may improve
outcome prediction models [132, 204]. In summary, while
GFAP is a promising marker of brain injury in both mild
and moderate-to-severe TBI, its kinetic profile and outcome
predictive effect are less studied compared to S100B’s.
Ubiquitin C-terminal hydrolase L1 (UCH-L1)
One of the newer serum brain biomarker candidates is UCH-
L1. UCH-L1 is a deubiquitinating enzyme modifying the c-
terminal adduct of the ubiquitin monomer present primarily in
neurons. Pre-clinical studies have been very promising with
increasing levels early after both TBI and stroke [95]. The
half-life in serum has been shown to be 11 h in TBI patients
[26]. In clinical studies, results show that it may be used to
screen for CT-verifiable lesions in mild TBI, but presents less
specificity than many studies using S100B [128, 143] and
does not provide the same accuracy over time to assess brain
injury as GFAP [127]. Moreover, in moderate-to-severe TBI,
while UCH-L1 levels have been shown to predict outcome,
they do not add significant independent information to more
extensive outcome models [142].
Neurofilament light (NF-L)
Neurofilaments, the main components of the axonal cytoskel-
eton, consist of three chains, where the protein NF-L consti-
tutes the smallest (68 kDa). CSF levels of NF-L are used as a
biomarker in multiple sclerosis to monitor effect of treatment
[55]. There are fewer studies on TBI, but it shows promising
results as a potential marker of injury severity as CSF samples
have been correlated to the extent of injury sustained during
boxing [118]. The serum half-life of NF-L is presumably long,
suggested to range up to 3 weeks [12]. In our group, we have
shown that the serum level of NF-L is a predictor of outcome
in moderate-to-severe TBI and adds independent information
significantly different from S100B [2]. This is perhaps not
surprising as it represents a very different tree of TBI patho-
physiology than S100B. However, this biomarker is not par-
ticularly dynamic in the early TBI stages and may not be
helpful for early prediction and monitoring purposes [2].
Conclusions
S100B levels in serum are a useful marker of brain tissue fate
in TBI. Several difficult clinical situations, such as determin-
ing the need for CT scanning in mild TBI, monitoring
unconscious TBI patients, predicting outcome and validating
treatment effect, may be facilitated by the use of S100B. The
emerging understanding of the kinetics of S100B may help
avoid pitfalls and increase its utility. Despite its shortcomings,
and if appropriately used, S100B is a valuable and yet under-
used tool for clinicians managing TBI patients. Future re-
search should focus on understanding and discriminating the
origin of ultra-early and later levels of S100B and on defining
age-related reference values for the pediatric population.
Furthermore, given the strong predictive value for outcome
in more severely injured TBI patients, we suggest that future
novel biomarker studies should be compared to S100B in
multivariate analyses including other known predictors, such
as the IMPACT variables.
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